Tech and Web NEWS

Lupus Drug Benlysta by Human Genome Sciences and GlaxoSmithKline looks promising

By Elizabeth Haggar for CEOWORLD Magazine Updated:November 2, 2009


Human Genome Sciences (NASDAQ:HGSI) and GlaxoSmithKline PLC (NYSE:GSK) announced Monday morning that BENLYSTA met the primary endpoint in the second of two Phase 3 trials in seropositive patients with systemic lupus erythematosus.

Companies hope will be the first treatment to receive approval for lupus in over 50 years.

The drug works by suppressing the immune system’s response to lupus, and if approved would be the leading drug on the market to treat the condition.

The drug was compared to placebo, in a trial of patients living with lupus, and proved without any doubt to be effective at reducing symptoms associated with the disease.

The results from the most recent clinical study were not as persuasive as those from the first study, however still looked strong enough to get the go-ahead from regulators and ensure doctors use the drug widely, industry analysts said on Monday. The companies need to give two positive clinical trials of a lupus drug for approval, so investors have waited nervously for Monday’s findings from the so-called Bliss-76 study of Benlysta ever since the positive data from the first study, Bliss-52, were released in July

The new study showed patients given a high dose of Benlysta had a statistically significant improvement in symptoms compared with patients who were given the placebo.

“The results from this second pivotal Phase 3 trial reinforce our belief that belimumab could deliver a significant therapeutic option for patients with lupus who have had no new treatment in 50 years. We look forward to continuing our collaboration with HGS in order to bring this important medicine to patients,” Carlo Russo, GlaxoSmithKline’s Senior Vice President, Biopharm Development, said.

Currently there is no cure for lupus, which triggers the immune system to attack healthy cells and affects approximately 5 million people around the world. London-based Glaxo and Human Genome Sciences, based in Rockville, Maryland, hope to sell the drug in the U.S., Europe and other countries in the first half of 2010, Human Genome Sciences Chief Executive Officer Thomas Watkins said in the statement.

glaxosmithkline

Related Reading:

TechCraft BCE48 Wide Home Theater Stand (Black)TechCraft BCE48 Wide Home Theater Stand (Black)Brilliant black glass with stylish curved front. Angled back design makes it great corner stand. Ample space for component storage and wire management
adidas Men's Tech-Fit Power Web Sleeveless Tee,Black,Smalladidas Men's Tech-Fit Power Web Sleeveless Tee,Black,SmallCLIMACOOL® compression sleeveless tee. Anatomically placed TPU banding to enhance athletic posture and movement, with compression properties to incre... Read More >
Scosche NN04B 2007-Up Nissan Car Stereo ConnectorScosche NN04B 2007-Up Nissan Car Stereo ConnectorScosche NN04B 2007-up Nissan car stereo connector
Words+Pictures=Web Marketing TechGet the inside spin on emarketing, technology & new media by digital marketer, photographer, copywriter, and comic book writer Buddy Scalera.Kindle bl... Read More >
Tech 4 O Women's Accelerator Pulse WatchTech 4 O Women's Accelerator Pulse WatchYou really don’t want guesswork when it comes to speed, distance, and heart rate measurements. The Pulse provides the chest strap heart rate monitor giving the best known accurate measure. Tech 4 0 delievrs the stats you need with 95+% accuracy. Accelerator Pulse will never let you down.
Share this Post:
  • Digg
  • del.icio.us
  • Facebook
  • Google Bookmarks
  • email
  • FriendFeed
  • LinkedIn
  • MySpace
  • RSS
  • StumbleUpon
  • Technorati
  • Yahoo! Buzz
  • Identi.ca
  • PDF
  • Wikio
  • Mixx
  • Print
  • Propeller
  • SphereIt
  • Sphinn
  • Suggest to Techmeme via Twitter
  • Tipd
Sphere: Related Content

Like this article!

Get our best articles delivered direct to your inbox at no cost. Sign up for CEOWORLD Magazine daily by entering your email below.


Readers Rating:
1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)
Loading ... Loading ...
Popularity:
17250 views
Leave a Comment:
add your comment
Tagged with: , , , , , , , , , , ,
  • DrugLord
    I think it is very good that you managed to find something useful against lupus,although it isnt found on the market I hope it will be found very soon so people wont loose their hope.


    _________________________________________
    Alcohol Treatment
blog comments powered by Disqus


Follow CEOWORLD Magazine

82358 RSS & 8000 Twitter Subscribers

Enter your email address:

Post a Job on CEOWORLD Magazine

Jobs on ceoworld

CEOWORLD Magazine on Facebook

Market summary



CEOWORLD News

Trinity Mirror buys Guardian Media Group (GMG) Regional Media business

Trinity Mirror Plc (TNI.LN), a multimedia business with leading print, online and TV brands, announced Tuesday that it h [...]

Redpoint Ventures raises $400 mln for start-ups in the Social and mobile and clean technology

Redpoint Ventures, which helps entrepreneurs to build innovative businesses announced that it had closed a new $400 mill [...]

Foodie Love- Foursquare signs a deal with Zagat to create media and entertainment mix

Foursquare, a location based social network that incorporates gaming elements, signs a deal with restaurant rating guide [...]

Naspers and DST Forticom in talks to pool Polish social networks Gadu-Gadu and Nasza-klasa.pl

DST (Digital Sky Technology) -owned holding Forticom, a Russian Internet holding company which holds a 75 percent stake [...]

Entertainment media company Galleon Holdings acquires 19% Stake in Dragonfruit Studios

Entertainment media company Galleon Holdings Plc, has acquired a 19% stake in Dragonfruit Studios LLC for US$1m. US$500, [...]

Advertisement!

CEOWORLD Magazine

Poland Business Guide


cosmos yachting LLC

lucentbyte


Global business networking



An International Business and Online Marketplace offers B2B Leads & promoting B2B Products of Worldwide Importers & Exporters


Get Chitika Premium

Thank you!



Quick Links:     Journalist Association of Europe Member   ·   Careers   ·   Subscription   ·   CEOWORLD Exchange   ·   Contact Us   ·   Terms of Use   ·   About us   ·   Advertise